STEPHEN B. ARNOLD, M.D.; ROGER L. WILLIAMS, M.D.; THOMAS A. PORTS, M.D.; ROBERT A. BAUGHMAN, Pharm. D.; LESLIE Z. BENET, Ph.D.; WILLIAM W. PARMLEY, M.D.; KANU CHATTERJEE, M.B.
ARNOLD SB, WILLIAMS RL, PORTS TA, BAUGHMAN RA, BENET LZ, PARMLEY WW, et al. Attenuation of Prazosin Effect on Cardiac Output in Chronic Heart Failure. Ann Intern Med. 1979;91:345-349. doi: 10.7326/0003-4819-91-3-345
Download citation file:
Published: Ann Intern Med. 1979;91(3):345-349.
The persistence of the hemodynamic effects of prazosin was studied in 12 patients with chronic congestive heart failure. Multidose evaluation involving five 5-mg doses showed the initial decrease in systemic vascular resistance and increase in cardiac index, stroke work index, and stroke volume index to be transient. Doubling the dose did not restore effect. Modest decreases in pulmonary capillary-wedge and mean arterial pressures persisted throughout the study. In six patients, plasma prazosin concentration measured at times of hemodynamic observations showed the initial hemodynamic effect of prazosin to attenuate upon further administration despite mean plasma concentrations that exceeded those measured after the first dose. In patients with chronic heart failure, resting hemodynamic studies suggest a rapid attenuation of prazosin-mediated hemodynamic effect in the presence of adequate plasma concentration. Recognizing this phenomenon, if long-term prazosin therapy for congestive heart failure is contemplated, we suggest the hemodynamic response in individual patients be monitored.
Learn more about subscription options.
Register Now for a free account.
Cardiology, Heart Failure, Cardiac Diagnosis and Imaging.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only